November 2021

NCETA’s new Director, Professor Jacqueline Bowden

We are delighted to announce NCETA’s new Director, Professor Jacqueline Bowden. Jacquie has a background in both psychology (BA Arts, Hons and PhD) and public health (Master of Public Health).

Read more
August 2020

Pregabalin use found to be relatively common among people who regularly inject drugs

A new NDARC study found the use of pregabalin is relatively common among a sample of people who regularly inject drugs in Australia.

August 2020

Pot, pills and the pandemic: How coronavirus is changing the way we use drugs

NDARC’s Dr Amy Peacock and Dr Rachel Sutherland share findings from two surveys of Australians who regularly use illicit drugs.

August 2020

Forthcoming tools and resources from NCETA to assist workers and organisations

There will be two new resources developed by NCETA aimed at assisting workers and organisations released soon

August 2020

Alcohol and the social determinants of health: An equity lens on interventions

Watch NCETA’s Dr Jane Fischer present a webinar for Australian Indigenous HealthInfoNet’s AOD Knowledge Centre.

August 2020

Interpersonal Violence & AOD: Working with patients & clients

For the 5th consecutive year, NCETA has partnered with the Queen Elizabeth Hospital to conduct a one-day workshop.

August 2020

Helping employers manage alcohol and other drug-related issues

Watch NCETA's Professor Ann Roche present a webinar on Alcohol and other drugs in the workplace…what employers need to know.

August 2020

The results are in! Insights from Australia’s first AOD workforce survey in over 10 years

Over 1500 AOD workers shared their experiences of working in the AOD sector in Australia’s Alcohol and Other Drug Workforce National Survey.

May 2020

Coronavirus (COVID-19) information and resources for the AOD sector

Online information and resources to assist people working in the alcohol and other drug sector at this challenging time.

May 2020

CoLAB study extended for 12 months to continue evaluation of extended release buprenorphine

The CoLAB study, led by NDARC at UNSW Sydney, has been extended for 12 months to continue evaluating outcomes, processes and costs of extended release buprenorphine.

May 2020

The cost of opioid use to Australia: $15.7 billion and 2200 deaths

New NDRI-led research on the social and economic costs of ‘extra-medical’ opioid use has been published.

Pages